ReviewInternational journal of environmental research and public health2021
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.
Review in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 7 syntheses or guidelines pooled it, 282 citations in OpenAlex.
- Therapeutic potential and mechanisms of flavonoids from Citrus grandis 'Tomentosa' in metabolic dysfunction-associated steatotic liver disease: a focus on immune-inflammatory signaling pathways.Frontiers in pharmacology · 2026Pooled it
- Evidence on the link between hypothyroidism and non-alcoholic fatty liver disease: an updated systematic review.BMC endocrine disorders · 2025Pooled it
- Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Prognostic biomarkers for predicting decompensation in alcoholic and non-alcoholic patients with compensated cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Molecular Pathways Linking High-Fat Diet and PMBiomolecules · 2024Pooled it
- Fruit and vegetable intake and the risk of non-alcoholic fatty liver disease: a meta-analysis of observational studies.Frontiers in nutrition · 2024Pooled it
- Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Ultrasound grading of hepatic steatosis and its metabolic and endocrine correlates among adults with MASLD in Duhok, Iraq: a cross-sectional study.Journal of ultrasound · 2026Article
- Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications.Nature reviews. Gastroenterology & hepatology · 2026Review
- Review
- Association of food insecurity with metabolic dysfunction-associated steatotic liver disease by sex and race/ethnicity.European journal of nutrition · 2026Article
- Impact of Air Pollution on Metabolic Dysfunction-Associated Fatty Liver Disease.International journal of molecular sciences · 2026Review
- The role of hepatocyte epigenetics in the pathogenesis of metabolic dysfunction-associated steatotic liver disease.Communications medicine · 2026Review
- Article
- Article
- Chronic TBPH Exposure Drives the Transition from Steatosis to Hepatic Fibrosis via Lipid Droplet Dysregulation in Zebrafish.Biology · 2026Article
- Glucagon-Like Peptide-2 Ameliorates Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Adiponectin-Adiponectin Receptor-Mediated AMPK/PPARalpha Pathway.Physiological research · 2026Article
- Wanshi Shachong Xiaoji Pills Alleviate Functional Dyspepsia in Mice and Exhibit Lipid-Lowering Effects in a Hepatocyte Steatosis Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Exercise as a Molecular Therapeutic Tool in MASLD: From Signaling Pathways to Clinical Translation-A Narrative Review.Biomedicines · 2026Review
- Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes.BMC medical genomics · 2026Review
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver disease in the Western world, probably due to the growing prevalence of obesity, metabolic diseases, and exposure to some environmental agents. In certain patients, simple hepatic steatosis can progress to non-alcoholic steatohepatitis (NASH), which can sometimes lead to liver cirrhosis and its complications including hepatocellular carcinoma. Understanding the mechanisms that cause the progression of NAFLD to NASH is crucial to be able to control the advancement of the disease. The main hypothesis considers that it is due to multiple factors that act together on genetically predisposed subjects to suffer from NAFLD including insulin resistance, nutritional factors, gut microbiota, and genetic and epigenetic factors. In this article, we will discuss the epidemiology of NAFLD, and we overview several topics that influence the development of the disease from simple steatosis to liver cirrhosis and its possible complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.